Nanfang Finance and Economics, on February 23, according to the official account of Genxi Biotechnology WeChat, Genxi Biotechnology Group announced that it had officially completed the merger agreement with AstraZeneca Group announced earlier. After the merger, Genxi Biotechnology will no longer be a listed company, but will become a wholly-owned subsidiary of the parent company. The company has requested Nasdaq to submit Form 25 to the United States Securities and Exchange Commission (SEC), notifying the SEC that the company will delist from Nasdaq.